11 – 19 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2017
-
Mark
Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day : An analysis using continuous glucose monitoring
(
- Contribution to journal › Article
- 2016
-
Mark
Efficacy of lixisenatide in patients with type 2 diabetes : A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
(
- Contribution to journal › Article
-
Mark
CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion
(
- Contribution to journal › Article
- 2011
-
Mark
GLP-1 for type 2 diabetes
(
- Contribution to journal › Scientific review
- 2010
-
Mark
Overexpression of Foxf2 in adipose tissue is associated with lower levels of IRS1 and decreased glucose uptake in vivo
(
- Contribution to journal › Article
-
Mark
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
(
- Contribution to journal › Article
- 2007
-
Mark
A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease.
(
- Contribution to journal › Article
- 2006
-
Mark
Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
(
- Contribution to journal › Article
- 2002
-
Mark
Role of islet amyloid in type 2 diabetes mellitus: consequence or cause?
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »